Abstract: A method for treating antiphospholipid syndrome by administering to a patient a pharmaceutical composition that contains S-(+)-hydroxychloroquine and a pharmaceutically acceptable excipient. The pharmaceutical composition is substantially free of R-(?)-hydroxychloroquine.

Abstract: Two crystals of (S)-(+)-hydroxychloroquine sulfate. One crystal features diffraction peaks at 12.3±0.1°, 13.1±0.1°, 17.9±0.1°, 22.8±0.1°, 23.4±0.1°, 25.1±0.1°, and 26.3±0.1° as 2? angles in a powder X-ray diffraction pattern. The other crystal features diffraction peaks at 12.8±0.1°, 14.5±0.1°, 16.7±0.1°, 17.6±0.1°, 20.2±0.1°, 21.4±0.1°, 23.8±0.1°, 25.7±0.1°, and 26.0±0.1° as 2? angles in a powder X-ray diffraction pattern. Also disclosed are methods of preparing crystals of (S)-(+)-hydroxychloroquine sulfate.

Abstract: A method for treating lupus erythematosus by administering to a patient a pharmaceutical composition that contains S-hydroxychloroquine (S-HCQ) and a pharmaceutically acceptable excipient. The pharmaceutical composition is essentially free of R-hydroxychloroquine (R-HCQ). The method is effective for treating cutaneous lupus erythematosus, systemic lupus erythematosus, and patients suffering from systemic lupus erythematosus that have concurrent lupus nephritis. Administration of S-HCQ in the claimed method has fewer side effects, particularly respecting cardiotoxicity, as compared to R-HCQ and to an equimolar mixture of S-HCQ and R-HCQ.

Abstract: Two crystals of (S)-(+)-hydroxychloroquine sulfate. One crystal features diffraction peaks at 12.3±0.1°, 13.1±0.1°, 17.9±0.1°, 22.8±0.1°, 23.4±0.1°, 25.1±0.1°, and 26.3±0.1° as 2? angles in a powder X-ray diffraction pattern. The other crystal features diffraction peaks at 12.8±0.1°, 14.5±0.1°, 16.7±0.1°, 17.6±0.1°, 20.2±0.1°, 21.4±0.1°, 23.8±0.1°, 25.7±0.1°, and 26.0±0.1° as 2? angles in a powder X-ray diffraction pattern. Also disclosed are methods of preparing crystals of (S)-(+)-hydroxychloroquine sulfate.

Abstract: Methods and apparatuses are provided for causing active hand-in of a device from a macrocell base station to a femto node, which can be an inter-frequency hand-in. The femto node can broadcast a beacon, which can be received and reported by a device to a source base station along with one or more parameters. The source base station can communicate a handover message to the femto node or a related femto gateway along with the one or more parameters. The femto node or femto gateway can disambiguate the intended target femto node based in part on the one or more parameters, which can include applying one or more filters. Applying the one or more filters may include applying an UL RSSI filter to the one or more femto nodes to determine whether presence of the device causes a rise in UL RSSI measured at the one or more femto nodes.

Abstract: A wireless power transmitter system includes: a power delivery structure comprising power transmitting elements (power transmitting elements), each of which is configured to induce a field, and configured to adapt to an exterior shape of an entity that contains a receiver; a power circuit configured to provide power to the power transmitting elements selectively; and a controller configured to: determine an electrical characteristic, other than power transfer to the receiver, associated with actuating at least one of the power transmitting elements; determine at least one power transmitting element subset, based on the electrical characteristic, containing less than all, and at least one, of the power transmitting elements; select, based on power transferred to the receiver, one or more charging power transmitting elements to use to charge the receiver wirelessly; and cause the power circuit to provide power to the one or more charging power transmitting elements.

Abstract: Devices and methods for distributing power are disclosed. For example, one device includes multiple assemblable elements, each assemblable element is configured to permit interlocking between one or more of the multiple assemblable elements. The multiple assemblable elements each include a portion of a coil. The portions of the coil are electrically interconnected and configured to provide wireless power to a receiving device.

Abstract: Methods and apparatuses are provided for causing active hand-in of a device from a macrocell base station to a femto node, which can be an inter-frequency hand-in. The femto node can broadcast a beacon, which can be received and reported by a device to a source base station along with one or more parameters. The source base station can communicate a handover message to the femto node or a related femto gateway along with the one or more parameters. The femto node or femto gateway can disambiguate the intended target femto node based in part on the one or more parameters, which can include applying one or more filters. Applying the one or more filters may include applying an UL RSSI filter to the one or more femto nodes to determine whether presence of the device causes a rise in UL RSSI measured at the one or more femto nodes.

Abstract: An antiemetic system for weekly application that contains two identical transdermal patches, a first patch and a second patch, the first patch to be administered to a subject for 3 days followed by administering the second patch to the subject for 4 days. Also disclosed is a method of treating an emesis in a subject with the above-described antiemetic system.

Abstract: A process for the recovery of sulfur from an acid gas stream is disclosed. The process includes a Claus sulfur recovery step in combination with a direct reduction step and a biological sulfur recovery step to provide a sweet gas stream having a very low concentration of hydrogen sulfide and sulfur dioxide. The process includes reacting an acid gas steam with oxygen under such oxidation conditions to yield a combustion gas comprising hydrogen sulfide and sulfur dioxide. The combustion gas is reacted under Claus reaction conditions to yield a reaction gas comprising sulfur. Sulfur is recovered from the reaction gas to yield a Claus tail gas comprising hydrogen sulfide and sulfur dioxide. The Claus tail gas is reacted under direct reduction reaction conditions to yield a direct reduction gas comprising sulfur. Sulfur is recovered from the direct reduction reaction gas to yield a tail gas comprising a concentration of hydrogen sulfide.

Abstract: A process for the recovery of sulfur from an acid gas stream is disclosed. The process includes a Claus sulfur recovery step in combination with a biological sulfur recovery step to provide a sweet gas stream having very low concentrations of hydrogen sulfide and sulfur dioxide. The process includes reacting an acid gas steam with oxygen under such oxidation conditions to yield a combustion gas comprising hydrogen sulfide and sulfur dioxide so as to have a ratio of hydrogen sulfide to sulfur dioxide exceeding 2:1, preferably from 2:1 to 30:1. The combustion gas is reacted under Claus reaction conditions to yield a reaction gas comprising sulfur. Sulfur is recovered from the reaction gas to yield a tail gas comprising a concentration of hydrogen sulfide and less than 1000 ppm sulfur dioxide. The tail gas is contacted with a lean absorbent thereby remove from the tail gas a portion of the hydrogen sulfide contained therein and to yield a sweet gas and a rich solvent comprising dissolved hydrogen sulfide.

Abstract: Methods and configurations are drawn to a plant in which an effluent gas with a sulfur dioxide content of more than 1.5% is mixed with a substantially sulfur dioxide free offgas from a contactor to form a mixed feed gas for a hydrogenation reactor, wherein the mixed feed gas has a sulfur dioxide content of less than 1.5%.

Abstract: A method for inhibiting cell infection by an enveloped virus, by administering to an infection site, a therapeutically effective amount of a calix(n)arene compound derivatized, at its ring positions meta to the bridge attachements to the ring, with polar substitutent having a terminal carboxylate, phosphate, or sulfonate groups, including esters and amides which are cleavable in vivo. The compound may be administered orally, or topically, e.g., for treatment of herpes virus.

Abstract: A method of inhibiting thrombus formation in a mammalian subject. The method involves administering to the subject a therapeutically effective dose of a calix(n)arene compound derivatized, at its ring positions meta to the bridge attachments to the ring, with polar substituents having terminal sulfonate groups, including esters and amides which are cleavable in vivo.

Abstract: A method of preparing a 4'-0-demethy-4.beta.-NHR podophyllotoxin, where R is an aryl or dialkyl amino alkyl group, is disclosed. The method includes reacting H.sub.2 NR under basic conditions with a mixture of .alpha. and .beta. epimers of 4'-0-demethyl-4-bromo-podophyllotoxin, to form an epimeric mixture of the 4'-0-demethyl-4-NHR-podophyllotoxin compounds, removing acidic impurities which bind to silica gel in a dichloromethane solvent, and crystallizing 4'-0-demethyl-4.beta.-NHR-podophyllotoxin from its .alpha. epimer.

Abstract: The invention relates to novel acyl derivatives of rifamycins of the formula ##STR1## and the salts thereof, in which the structural elements --A.sub.1 --A.sub.2 --, --A.sub.3 --A.sub.4 -- and --A.sub.5 --A.sub.6 -- each denote ethylene or vinylene or the elements --A.sub.1 --A.sub.2 -- and --A.sub.3 --A.sub.4 -- each denote ethylene and --A.sub.5 --A.sub.6 -- denotes vinylene; X represents >C(R.sub.6)-- or >N-- and R.sub.6 denotes hydrogen or alkyl; alk denotes an aliphatic hydrocarbon radical; R.sub.1 denotes hydrogen or acyl; R.sub.2 denotes acyl, or alkyl which is optionally substituted by an aromatic radical, and R.sub.3 and R.sub.3 ' represent a common bond, or R.sub.3 denotes hydrogen or acyl, and R.sub.3 ' is hydrogen; R.sub.4 denotes hydrogen, cycloalkyl or aryl; R.sub.5 denotes hydrogen or acetyl; R.sub.7 denotes hydrogen or alkyl, which can be used as active compounds in medicaments, the preparation and use thereof, and pharmaceutical products and the preparation thereof.

Abstract: The compound of the formula I ##STR1## wherein R, R.sub.3 and R.sub.5 independently represent hydrogen or hydroxy provided that at least one of R, R.sub.3 and R.sub.5 represents hydroxy; R.sub.1 represents hydrogen, lower alkyl, C.sub.3 -C.sub.7 -alkenyl, hydroxy-lower alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, adamantyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyranyl-lower alkyl, tetrahydrothiopyranyl-lower alkyl, adamantyl-lower alkyl, aryl-hydroxy-lower alkyl, aryl, aryl-lower alkyl, aryl-C.sub.3 -C.sub.6 -cycloalkyl, 9-fluorenyl, 9-fluorenyl-lower alkyl or cycloalkenyl-lower alkyl; or R.sub.

Abstract: The invention relates to novel substituted azacyclohexyl derivatives of formula ##STR1## and salts of thereof in which the structural elements --A.sub.1 -A.sub.2, --A.sub.3 -A.sub.4 -- and --A.sub.5 -A.sub.6 -- are each ethylene or vinylene or the elements --A.sub.1 -A.sub.2 -- and --A.sub.3 -A.sub.4 -- are each ethylene and --A.sub.5 -A.sub.6 -- is vinylene, X is >CR.sub.6 -- or >N-- and R.sub.6 is alkyl or hydrogen, alk is an aliphatic hydrocarbon radical or a bond, R.sub.1 is hydrogen or acyl, R.sub.2 is hydrogen or acetyl, R.sub.3 and R.sub.4 together are a bond or each is hydrogen, R.sub.5 is hydrogen, a cycloaliphatic hydrocarbon radical, aryl or heteroaryl and R.sub.7 is hydrogen or alkyl, with the proviso that when --A.sub.1 -A.sub.2 --, --A.sub.3 -A.sub.4 -- and --A.sub.5 -A.sub.6 -- are each vinylene, X is >N--, R.sub.1 is hydrogen or trialkylacetyl, R.sub.2 is hydrogen or acetyl, R.sub.3 and R.sub.4 together are a bond and alk is methylene, R.sub.

Abstract: The compound of the formula I ##STR1## wherein R, R.sub.3 and R.sub.5 independently represent hydrogen or hydroxy provided that at least one of R, R.sub.3 and R.sub.5 represents hydroxy; R.sub.1 represents hydrogen, lower alkyl, C.sub.3 -C.sub.7 -alkenyl, hydroxy-lower alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, adamantyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyranyl-lower alkyl, tetrahydrothiopyranyl-lower alkyl, adamantyl-lower alkyl, aryl-hydroxy-lower alkyl, aryl, aryl-lower alkyl, aryl-C.sub.3 -C.sub.6 -cycloalkyl, 9-fluorenyl, 9-fluorenyl-lower alkyl or cycloalkenyl-lower alkyl; or R.sub.

Abstract: A remote-control radio vacuum cleaner comprises a remote control device having radio transmitting circuits matched with a control mechanism for generating various control signals, and a separate vacuum cleaner structure disposed with vacuum cleaning fittings for dust suction operations, a storage battery system for supplying the required power in the vacuum cleaning structure, a radio receiving circuit disposed with respect to the transmitting circuits, and d.c. motors arranged in conjunction with the radio receiving circuit for moving the vacuum cleaner in performing dust cleaning work under the control of the remote control device.